|

[18F]-APN-1607 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • JYAMS PET Research & Development Limited1

Indications

  • Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia1
  • Alzheimer's Disease1

Other1 trial

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.